Biogen and Ionis announced that BIIB080/IONIS-MAPTRx, an antisense drug, demonstrated robust time and dose-dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period. Click here to learn more.

The lecture will be given in November at the Methodist Hospital (Houston). The invitation was extended by Dr. Stanley Appel, Chair of the Department of Neurology and Co-Director of the Methodist Neurological Institute.

This disappointing result was unexpected based on preclinical studies undertaken by Ionis Pharmaceuticals who, along with the Center, has championed the use of antisense therapeutics for treating neurologic disorders. Click here for more information.